Hormonal correlation suggests gonadotrophin-releasing hormone (GnRH) agonist or antihormonal therapy (tamoxifen) as emerging therapies, either as an adjuvant approach for residual mass or before surgery to minimize tumour size, and may increase the chance of complete excision [37]. Here, GNRH1 is linked to neoplasm.